Loading...
Loading...
IMRX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 15.3M |
| Operating I/L | -15.3M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.5M |
| Pretax | -14.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -14.6M |
Immuneering Corporation is a biopharmaceutical company specializing in the development of oncology and neuroscience product candidates. Its lead products include IMM-1-104, a dual-MEK inhibitor targeting RAS and RAF mutations in various cancers, and IMM-6-415 for solid tumors. The company also has five oncology programs and two neuroscience programs in the discovery stage, focusing on the MAPK, mTOR pathway, and other relevant targets. Immuneering Corporation generates revenue through the development and potential commercialization of these product candidates for the treatment of cancer and neurological disorders.
